Skip to main content

Advertisement

Table 1 Antimicrobial and anticancer screening results of synthesized analogues

From: Design, synthesis and therapeutic potential of 3-(2-(1H-benzo[d]imidazol-2-ylthio)acetamido)-N-(substituted phenyl)benzamide analogues

Compounds Minimum inhibitory concentration (MIC = μM) IC50 (μM)
Bacterial species Fungal species Cancer cell line (HCT116)
Gram +ve Gram −ve
SA ST KP CA AN
W1 10.15 10.15 10.15 5.08 5.08 > 20.31
W2 11.17 11.17 11.17 5.59 5.59 > 22.35
W3 11.17 11.17 11.17 5.59 5.59 > 22.35
W4 11.17 11.17 11.17 5.59 5.59 > 22.35
W5 10.39 10.39 10.39 5.19 5.19 > 20.77
W6 5.19 5.19 5.19 5.19 5.19 > 20.75
W7 11.44 11.44 11.44 5.72 5.72 > 22.89
W8 11.44 11.44 11.44 11.44 5.72 > 22.89
W9 11.61 11.61 11.61 11.61 5.81 > 23.23
W10 11.61 11.61 11.61 5.81 5.81 > 23.23
W11 12.00 12.00 12.00 6.00 6.00 > 24.01
W12 10.38 10.38 10.38 10.38 5.19 7.08
W13 11.44 11.44 11.44 5.72 5.72 > 22.89
W14 12.42 12.42 12.42 12.42 6.21 > 24.84
W15 11.56 11.56 11.56 11.56 5.78 23.12
W16 11.56 11.56 11.56 11.56 5.78 > 23.12
W17 11.56 11.56 11.56 11.56 5.78 4.12
W18 11.89 11.89 11.89 11.89 5.95 > 23.78
W19 11.89 11.89 11.89 11.89 5.95 > 23.78
W20 11.61 11.61 11.61 11.61 5.81 11.61
W21 10.39 10.39 10.39 10.39 5.19 > 20.77
DMSO NA NA NA NA NA > 1.44
Broth control NG NG NG NG NG
Ofloxacin 1.73 1.73 1.73
Fluconazole 8.16 8.16
5-Florouracil 7.69
  1. SA: Staphylococcus aureus (MTCC3160); ST: Salmonella typhi (MTCC3231); KP: Klebsiella pneumonia (MTCC9024); CA: Candida albicans (MTCC281) and AN: Aspergillus niger (MTCC227); DMSO: dimethyl sulfoxide; NA: no activity; NG: no growth